
TG Therapeutics
(NASDAQ) TGTX
TG Therapeutics Financials at a Glance
Market Cap
$5.73B
Revenue (TTM)
$700.35M
Net Income (TTM)
$461.90M
EPS (TTM)
$2.87
P/E Ratio
13.04
Dividend
$0.00
Beta (Volatility)
1.84 (High)
Dividend
$0.00
Beta (Volatility)
1.84 (High)
Price
$36.62
Volume
1,528,302.998
Open
$36.85
Price
$36.62
Volume
1,528,302.998
Open
$36.85
Previous Close
$36.64
Daily Range
$36.48 - $37.29
52-Week Range
$25.28 - $44.65
Dividend
$0.00
Beta (Volatility)
1.84 (High)
Price
$36.62
Volume
1,528,302.998
Open
$36.85
Previous Close
$36.64
Daily Range
$36.48 - $37.29
52-Week Range
$25.28 - $44.65
TGTX News

Best Biotech ETFs to Buy in 2026

TGTX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout TG Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
399
CEO
Michael Sean Weiss
Website
www.tgtherapeutics.comHeadquarters
Morrisville, NY 10014, US
TGTX Financials
Key Financial Metrics (TTM)
Gross Margin
83%
Operating Margin
21%
Net Income Margin
66%
Return on Equity
113%
Return on Capital
11%
Return on Assets
30%
Earnings Yield
7.67%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$5.73B
Shares Outstanding
153.08M
Volume
1.53M
Avg. Volume
2.03M
Financials (TTM)
Gross Profit
$515.57M
Operating Income
$123.32M
EBITDA
$134.36M
Operating Cash Flow
-$24.77M
Capital Expenditure
-$214.00K
Free Cash Flow
-$24.99M
Cash & ST Invst.
$141.97M
Total Debt
$260.73M
TG Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$204.92M
+69.6%
Gross Profit
$171.41M
+62.8%
Gross Margin
83.65%
N/A
Market Cap
$5.73B
N/A
Market Cap/Employee
$16.27M
N/A
Employees
352
N/A
Net Income
$19.78M
+290.8%
EBITDA
$34.80M
+183.3%
Quarterly Fundamentals
Net Cash
-$239.13M
-1161.3%
Accounts Receivable
$392.05M
+106.2%
Inventory
$129.03M
-18.2%
Long Term Debt
$751.74M
+197.6%
Short Term Debt
$1.82M
+63.3%
Return on Assets
30.21%
N/A
Return on Invested Capital
11.14%
N/A
Free Cash Flow
-$17.95M
+37.6%
Operating Cash Flow
-$17.89M
+37.7%





